Iniparib: Difference between revisions

Latest revision as of 03:50, 13 February 2025

Iniparib[edit]

Iniparib is a small molecule that was investigated as a potential anticancer drug. It was initially thought to be a PARP inhibitor, but subsequent studies suggested that its mechanism of action might be different from other drugs in this class.

Mechanism of Action[edit]

Iniparib was originally believed to inhibit poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. PARP inhibitors are a class of drugs that exploit the concept of synthetic lethality to target cancer cells, particularly those with BRCA1 or BRCA2 mutations. However, further research indicated that Iniparib might not function as a true PARP inhibitor, and its exact mechanism of action remains unclear.

Clinical Development[edit]

Iniparib was tested in several clinical trials for the treatment of triple-negative breast cancer (TNBC) and other types of cancer. Early-phase trials showed promising results, leading to its evaluation in larger, randomized studies.

Triple-Negative Breast Cancer[edit]

Triple-negative breast cancer is a subtype of breast cancer that lacks estrogen receptor, progesterone receptor, and HER2/neu expression. It is often more aggressive and has fewer treatment options compared to other breast cancer subtypes. Iniparib was studied in combination with chemotherapy agents such as gemcitabine and carboplatin in patients with TNBC.

Results and Challenges[edit]

While initial studies suggested potential benefits, subsequent phase III trials did not demonstrate a significant improvement in overall survival or progression-free survival when Iniparib was added to standard chemotherapy regimens. These results led to a reevaluation of its development as a cancer therapeutic.

Current Status[edit]

As of the latest updates, Iniparib is not approved for clinical use, and its development has been largely discontinued. The case of Iniparib highlights the challenges in drug development, particularly in understanding the precise mechanisms of action and the importance of robust clinical trial data.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Iniparib''' is a [[drug]] that was initially believed to be a [[PARP inhibitor]], which are a group of pharmacological inhibitors of the enzyme called [[Poly (ADP-ribose) polymerase]]. It was developed by [[Sanofi-Aventis]] for the treatment of various types of [[cancer]], including [[breast cancer]] and [[lung cancer]]. However, later studies suggested that Iniparib does not work by inhibiting PARP.
+== Iniparib ==
-== History ==
+[[File:Iniparib.svg|thumb|right|Chemical structure of Iniparib]]
-Iniparib was first developed by Sanofi-Aventis, a global pharmaceutical company. It was initially classified as a PARP inhibitor, a type of drug that prevents the repair of DNA damage in cancer cells, thereby leading to their death. Early clinical trials showed promise, particularly in the treatment of triple-negative breast cancer, a subtype of breast cancer that is particularly difficult to treat.
+'''Iniparib''' is a small molecule that was investigated as a potential [[anticancer drug]]. It was initially thought to be a [[PARP inhibitor]], but subsequent studies suggested that its mechanism of action might be different from other drugs in this class.
-However, later studies, including a Phase III clinical trial, failed to confirm these initial positive results. Furthermore, subsequent research suggested that Iniparib does not function as a PARP inhibitor. The exact mechanism of action of Iniparib remains unclear.
+== Mechanism of Action ==
-== Mechanism of Action ==
+Iniparib was originally believed to inhibit [[poly (ADP-ribose) polymerase]] (PARP), an enzyme involved in [[DNA repair]]. PARP inhibitors are a class of drugs that exploit the concept of [[synthetic lethality]] to target cancer cells, particularly those with [[BRCA1]] or [[BRCA2]] mutations. However, further research indicated that Iniparib might not function as a true PARP inhibitor, and its exact mechanism of action remains unclear.
+== Clinical Development ==
+Iniparib was tested in several [[clinical trials]] for the treatment of [[triple-negative breast cancer]] (TNBC) and other types of cancer. Early-phase trials showed promising results, leading to its evaluation in larger, randomized studies.
+=== Triple-Negative Breast Cancer ===
-The exact mechanism of action of Iniparib is not fully understood. It was initially believed to function as a PARP inhibitor, preventing the repair of DNA damage in cancer cells and thereby leading to their death. However, later research suggested that it does not inhibit PARP.
+Triple-negative breast cancer is a subtype of breast cancer that lacks [[estrogen receptor]], [[progesterone receptor]], and [[HER2/neu]] expression. It is often more aggressive and has fewer treatment options compared to other breast cancer subtypes. Iniparib was studied in combination with [[chemotherapy]] agents such as [[gemcitabine]] and [[carboplatin]] in patients with TNBC.
-Despite this, Iniparib has been shown to have anti-cancer effects. It is thought to work by forming toxic adducts with proteins and DNA in cancer cells, leading to their death. However, more research is needed to fully understand how Iniparib works.
+=== Results and Challenges ===
-== Clinical Trials ==
+While initial studies suggested potential benefits, subsequent phase III trials did not demonstrate a significant improvement in overall survival or progression-free survival when Iniparib was added to standard chemotherapy regimens. These results led to a reevaluation of its development as a cancer therapeutic.
-Iniparib has undergone several clinical trials for various types of cancer. Early trials showed promise, particularly for the treatment of triple-negative breast cancer. However, a Phase III clinical trial failed to confirm these initial positive results.
+== Current Status ==
-Despite these setbacks, Iniparib continues to be studied for potential use in treating other types of cancer, including lung cancer and ovarian cancer.
+As of the latest updates, Iniparib is not approved for clinical use, and its development has been largely discontinued. The case of Iniparib highlights the challenges in drug development, particularly in understanding the precise mechanisms of action and the importance of robust clinical trial data.
-== See Also ==
+== Related Pages ==
 * [[PARP inhibitor]]
-* [[Sanofi-Aventis]]
+* [[Triple-negative breast cancer]]
-* [[Breast cancer]]
+* [[Chemotherapy]]
-* [[Lung cancer]]
+* [[BRCA1]]
+* [[BRCA2]]
-[[Category:Drugs]]
+[[Category:Experimental cancer drugs]]
-[[Category:Cancer treatments]]
+[[Category:Antineoplastic drugs]]
-[[Category:Pharmacology]]
-{{Pharma-stub}}
-{{Cancer-stub}}
-{{Medicine-stub}}